Biomarkers to predict relapse risk in localized clear cell kidney cancer
Official title: Combination of Transcriptomic and Metallomic Biomarkers for Risk Assessment in Locoregional Clear Cell Renal Cell Carcinoma
Funded at University of California at Davis · NIH-11369856 · Data updated 2026-11-12
A clinician-scientist is studying blood and tissue biomarkers to identify which kidney cancer patients are at higher risk of returning after tumor removal.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | September 16, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $261,072 |
| NIH project number | 5K08CA273542-05 |
| Project ID | NIH-11369856 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with localized or locally advanced clear cell renal cell carcinoma who have undergone surgical resection.
✕Less likely to help
Patients with non-clear-cell RCC or those not undergoing or eligible for adjuvant therapies may not benefit.
What this research studies
This mixed bench-to-bedside grant supports mentored development to become an independent translational researcher. It focuses on finding biomarkers from gene activity and copper-related mitochondrial chemistry to predict relapse after kidney tumor surgery. The project plans to use patient samples and laboratory analyses to group tumors into high- and low-risk categories for early return of cancer. The goal is to guide future adjuvant therapy decisions and improve personalized care for patients with localized ccRCC.
Why it matters
Potential benefit: If successful, patients could receive more tailored post-surgery therapy, potentially reducing relapse and improving survival.
How similar studies have gone: Previous studies have shown that transcriptomic and molecular biomarkers can help predict relapse in kidney cancer, but robust, clinically actionable panels are still being developed.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Gulati, Shuchi — University of California at Davis
- Study coordinator: Gulati, Shuchi
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.